We're proud to receive a 2025 CDMO Leadership Award in the “Small Molecule Dosage Form” global category.
Intellectual property (IP) rights and confidentiality protections play a critical role in biopharmaceutical development and manufacturing. Appropriate protections enable developers to drive innovation, safeguard investments, and accelerate the development of new drugs and therapies, while creating a favorable environment for research, development, and commercialization.
Partnering with a CDMO with the global expertise to navigate complex landscape requirements, and with global frameworks in place to standardize protections, can alleviate potential challenges for drug developers and IP owners.